Good Health Can’t Wait.

More documents

Recommendations

Info

Good Health Can’t Wait. Dr. Reddy’s Laboratories Limited NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated) 2.8: NON CURRENT INVESTMENTS (CONTINUED) PARTICULARS AS AT 31 MARCH 2015 AS AT 31 MARCH 2014 Unquoted trade investments (continued) In other companies Equity shares (fully paid-up) Ordinary shares of Biomed Russia Limited, Russia (b) 66 66 200,000 (previous year: 200,000) ordinary shares of ` 10/- each of Altek Engineering Limited, India 2 2 8,859 (previous year: 8,859) equity shares of ` 100/- each of Jeedimetla Effluent Treatment Limited, India 1 1 24,000 (previous year: 24,000) equity shares of ` 100/- each of Progressive Effluent Treatment Limited, India 2 2 20,250 (previous year: 20,250) equity shares of ` 10/- each of Shivalik Solid Waste Management Limited, India (c) - - 71 71 Less: Provision for decline, other than temporary, in the value of non current investments (70) (70) Total unquoted trade investments in equity shares of other companies, net (C) 1 1 Total unquoted non current investments ( II ) (A+B+C) 17,598 17,398 Total (I + II) 17,601 17,401 Aggregate amount of quoted investments 3 3 Aggregate amount of unquoted investments 18,868 18,668 Aggregate provision for diminution in value of investments 1,270 1,270 Market value of quoted investments 32 23 (a) In respect of shares of State Bank of India, the share certificates were misplaced during transfer/lost in transit. The Company has initiated necessary legal action at the appropriate courts. (b) Shares held in Kunshan Rotam Reddy Pharmaceutical Co. Limited, China and Biomed Russia Limited, Russia are not denominated in number of shares as per the laws of the respective countries. (c) Rounded off in millions in the note above. 2.9: LONG TERM LOANS AND ADVANCES PARTICULARS AS AT 31 MARCH 2015 AS AT 31 MARCH 2014 Unsecured Considered good Loans and advances to wholly owned subsidiaries (a) 2,283 3,990 Advance income tax (net of provisions ` 26,557; previous year: ` 22,146) 1,576 903 MAT credit entitlement 644 - Capital advances for purchase of fixed assets 610 67 Security deposits 418 391 Other advances 7 7 Considered doubtful Loans and advances to wholly owned subsidiaries (a) 1,059 866 Others 8 8 6,605 6,232 Less: Provision for doubtful loans and advances (Refer Note 2.36) (1,067) (874) 5,538 5,358 130
Standalone Financial Statements Annual Report 2014 - 15 NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated) 2.9: LONG TERM LOANS AND ADVANCES (CONTINUED) (a) Loans and advances to wholly owned subsidiaries comprise: PARTICULARS BALANCE AS AT MAXIMUM AMOUNT OUTSTANDING AT ANY TIME DURING THE YEAR ENDED 31 MARCH 2015 31 MARCH 2014 31 MARCH 2015 31 MARCH 2014 DRL Impex Limited, India 759 2,045 2,061 2,603 Reddy Antilles N.V., Netherlands 324 311 331 353 Dr. Reddy’s Laboratories Romania SRL, Romania - 26 27 29 Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil 302 290 308 329 Industrias Quimicas Falcon de Mexico S.A. de C.V., Mexico 1,957 2,184 2,265 2,184 Cheminor Investments Limited, India (b) - - - - Dr. Reddy’s Bio-sciences Limited, India (b) - - - - 3,342 4,856 (b) Rounded off in millions in the note above. (c) The settlement of loans and advances to wholly owned subsidiaries is neither planned nor likely to occur in the next twelve months. Loans given to Reddy Antilles N.V., Netherlands, Dr. Reddy’s Laboratories Romania SRL, Romania, Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil, Cheminor Investments Limited, India and Dr. Reddy’s Bio-sciences Limited, India are interest free. Other loans carry the following rates of interest: Loan to Interest rate per annum DRL Impex Limited, India 1.75% Industrias Quimicas Falcon de Mexico S.A. de C.V., Mexico 9% (d) Loans and advances to wholly owned subsidiaries are given for the purpose of working capital and other business requirements. 2.10: CURRENT INVESTMENTS PARTICULARS AS AT 31 MARCH 2015 AS AT 31 MARCH 2014 Current investments at cost or fair value whichever is lower Quoted investments In Mutual Funds 1,077,125.72 (previous year: Nil) units of HSBC Cash Fund - Direct plan - Growth 1,500 - 5,179,111.81 (previous year: Nil) units of ICICI PRU Money Market Fund - Direct Plan - Growth 1,000 - 323,235.94 (previous year: Nil) units of SBI Magnum Insta Cash plan - Direct Plan - Growth 1,000 - 5,645,004.92 (previous year: Nil) units of Birla Sun Life Treasury Optimizer Plan - Growth - Direct Plan 950 - 52,118,621.98 (previous year: Nil) units of JPMorgan India Active Bond Fund - Direct Plan - Growth Option 800 - 30,835,232.65 (previous year: Nil) units of Reliance Short Term Fund - Direct Plan - Growth 800 - 34,380,315.6 (previous year: Nil) units of IDFC Super Saver Income Fund Medium Term Plan - Direct Plan -Growth 797 - 26,714,767.68 (previous year: Nil) units of IDFC Super Saver Income Fund Short Term Plan Growth Direct 749 - 41,901,855.65 (previous year: Nil) units of Axis Short Term Fund - Direct Plan- Growth 600 - 21,501,954.53 (previous year: Nil) units of HSBC Income Fund Short Term Plan Growth Direct Plan 500 - 17,169,327.34 (previous year: Nil) units of HDFC Cash Management Fund - Savings Plan Growth 500 - 442,568.54 (previous year: Nil) units of L&T Cash Fund - Direct Plan Growth 500 - 17,284,292.04 (previous year: Nil) units of Reliance Medium Term Fund - Direct Plan - Growth 500 - 259,865.94 (previous year: Nil) units of Reliance Money Manager Fund - Direct Plan - Growth 500 - 193,949.96 (previous year: Nil) units of TATA Liquid Fund - Direct Plan - Growth 500 - 45,394,706.98 (previous year: Nil) units of HDFC Banking & PSU Debt Fund - Direct Plan - Growth 500 - 2,415,432.1 (previous year: Nil) units of ICICI Pru Liquid Plan - Direct Plan - Growth 500 - 9,658,401.65 (previous year: Nil) units of Birla Sun Life Short Term Fund - Growth Direct Plan 500 - 19,165,753.09 (previous year: Nil) units of Tata Short Term Bond Fund Direct Plan Growth 500 - 131
Page 1 and 2:
ANNUAL REPORT 2014-15 Good Health C
Page 3 and 4:
Our Brand We are in the business of
Page 5 and 6:
Corporate Overview Annual Report 20
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Statutory Reports • Business Resp
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Statutory Reports • Management Di
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Statutory Reports • Corporate Gov
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Statutory Reports • Additional Sh
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82: Statutory Reports • Additional Sh
Page 87 and 88: Statutory Reports • Board’s Rep
Page 111 and 112: Standalone Financial Statements Ann
Page 131: Standalone Financial Statements Ann
Page 165 and 166: Consolidated Financial Statements A
Page 183 and 184:
Consolidated Financial Statements A
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Notice Annual Report 2014 - 15 NOTI
Page 229 and 230:
E-Voting Annual Report 2014 - 15 IN
Page 231:
Dr. Reddy’s Laboratories Limited
Page 235 and 236:
The future belongs, not to those wh
show all

Good Health Can’t Wait.

Create successful ePaper yourself

Delete template?

Save as template?